Myriad Genetics Inc, Salt Lake City, Utah.
Department of Medicine, Stanford University, Palo Alto, California.
JAMA Netw Open. 2020 Jul 1;3(7):e208501. doi: 10.1001/jamanetworkopen.2020.8501.
To date, few studies have examined the extent to which polygenic single-nucleotide variation (SNV) (formerly single-nucleotide polymorphism) scores modify risk for carriers of pathogenic variants (PVs) in breast cancer susceptibility genes. In previous reports, polygenic risk modification was reduced for BRCA1 and BRCA2 PV carriers compared with noncarriers, but limited information is available for carriers of CHEK2, ATM, or PALB2 PVs.
To examine an 86-SNV polygenic risk score (PRS) for BRCA1, BRCA2, CHEK2, ATM, and PALB2 PV carriers.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective case-control study using data on 150 962 women tested with a multigene hereditary cancer panel between July 19, 2016, and January 11, 2019, was conducted in a commercial testing laboratory. Participants included women of European ancestry between the ages of 18 and 84 years.
Multivariable logistic regression was used to examine the association of the 86-SNV score with invasive breast cancer after adjusting for age, ancestry, and personal and/or family cancer history. Effect sizes, expressed as standardized odds ratios (ORs) with 95% CIs, were assessed for carriers of PVs in each gene as well as for noncarriers.
The median age at hereditary cancer testing of the population was 48 years (range, 18-84 years); there were 141 160 noncarriers in addition to carriers of BRCA1 (n = 2249), BRCA2 (n = 2638), CHEK2 (n = 2564), ATM (n = 1445), and PALB2 (n = 906) PVs included in the analysis. The 86-SNV score was associated with breast cancer risk in each of the carrier populations (P < 1 × 10-4). Stratification was more pronounced for noncarriers (OR, 1.47; 95% CI, 1.45-1.49) and CHEK2 PV carriers (OR, 1.49; 95% CI, 1.36-1.64) than for carriers of BRCA1 (OR, 1.20; 95% CI, 1.10-1.32) or BRCA2 (OR, 1.23; 95% CI, 1.12-1.34) PVs. Odds ratios for ATM (OR, 1.37; 95% CI, 1.21-1.55) and PALB2 (OR, 1.34; 95% CI, 1.16-1.55) PV carrier populations were intermediate between those for BRCA1/2 and CHEK2 noncarriers.
In this study, the 86-SNV score was associated with modified risk for carriers of BRCA1, BRCA2, CHEK2, ATM, and PALB2 PVs. This finding supports previous reports of reduced PRS stratification for BRCA1 and BRCA2 PV carriers compared with noncarriers. Modification of risk in CHEK2 carriers associated with the 86-SNV score appeared to be similar to that observed in women without a PV. Larger studies are needed to provide more refined estimates of polygenic modification of risk for women with PVs in other moderate-penetrance genes.
迄今为止,很少有研究探讨多基因单核苷酸变异(SNV)(以前称为单核苷酸多态性)评分对乳腺癌易感性基因致病性变异(PV)携带者风险的影响程度。在以前的报告中,与非携带者相比,BRCA1 和 BRCA2 PV 携带者的多基因风险修饰作用降低,但对于 CHEK2、ATM 或 PALB2 PV 携带者的信息有限。
研究 BRCA1、BRCA2、CHEK2、ATM 和 PALB2 PV 携带者的 86-SNV 多基因风险评分(PRS)。
设计、地点和参与者:使用 2016 年 7 月 19 日至 2019 年 1 月 11 日期间在一家商业检测实验室进行的多基因遗传性癌症面板检测的 150962 名女性的数据,进行了一项回顾性病例对照研究。参与者包括年龄在 18 岁至 84 岁之间的欧洲血统女性。
多变量逻辑回归用于在调整年龄、祖源、个人和/或家族癌症史后,研究 86-SNV 评分与侵袭性乳腺癌之间的关联。评估了每个基因的 PV 携带者(BRCA1 [n=2249]、BRCA2 [n=2638]、CHEK2 [n=2564]、ATM [n=1445]和 PALB2 [n=906])和非携带者的效应大小,以标准化优势比(OR)和 95%置信区间(CI)表示。
人群中遗传性癌症检测的中位年龄为 48 岁(范围为 18-84 岁);除了 BRCA1(n=2249)、BRCA2(n=2638)、CHEK2(n=2564)、ATM(n=1445)和 PALB2(n=906)的 PV 携带者外,还有 141160 名非携带者包括在分析中。86-SNV 评分与每个携带者群体的乳腺癌风险相关(P<1×10-4)。非携带者(OR,1.47;95%CI,1.45-1.49)和 CHEK2 PV 携带者(OR,1.49;95%CI,1.36-1.64)的分层更为明显,而非 BRCA1(OR,1.20;95%CI,1.10-1.32)或 BRCA2(OR,1.23;95%CI,1.12-1.34)的携带者。ATM(OR,1.37;95%CI,1.21-1.55)和 PALB2(OR,1.34;95%CI,1.16-1.55)PV 携带者群体的 OR 介于 BRCA1/2 和 CHEK2 非携带者之间。
在这项研究中,86-SNV 评分与 BRCA1、BRCA2、CHEK2、ATM 和 PALB2 PV 携带者的风险修饰有关。这一发现支持了先前关于 BRCA1 和 BRCA2 PV 携带者与非携带者相比,PRS 分层作用降低的报告。与 86-SNV 评分相关的 CHEK2 携带者的风险修饰作用似乎与未携带 PV 的女性观察到的风险修饰作用相似。需要更大规模的研究来提供其他中度外显率基因中携带 PV 的女性风险修饰的更精确估计。